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Chronic Kidney Disease as a Public Health Problem 
Chronic kidney disease (CKD) is a worldwide public health problem with a rising 
incidence and prevalence of kidney failure, with poor outcomes and high cost1. There is 
an even higher prevalence of earlier stages of CKD, which often goes unnoticed. 
Even  in  affluent  western  countries,  despite  the  magnitude  of  the  resources 
committed  to  the  treatment  of  Chronic  Kidney  Disease  stage  5  (CKD  5)  and  the 
substantial  improvements in the quality of dialysis  therapy; these patients  continue to 
experience significant mortality and morbidity, and a reduced quality of life. Survival 
probabilities for dialysis patients at 1, 2, 5 and 10 years are approximately 80, 67, 40, and 
18 percent, respectively2. 
Moreover, 50 percent of dialysis patients have three or more comorbid conditions, 
the mean number of hospital days per year is approximately 14 per patient, and self-
reported quality of life is far lower in dialysis patients than in the general population.3, 4
In  the  past  two decades,  there  has  been  increasing  evidence  that  the  adverse 
outcomes of CKD, such as kidney failure, cardiovascular disease, and premature death, 
can be prevented or delayed. Earlier stages of CKD can be detected only through periodic 
health check-ups and laboratory testing. Treatment of earlier stages of CKD is effective 
in slowing the progression toward stage 5. Initiation of treatment for cardiovascular risk 
factors at earlier stages of CKD should be effective in reducing cardiovascular disease 
events both before and after the onset of kidney failure1. Unfortunately, CKD is “under- 
diagnosed” and “under-treated” resulting in lost opportunities for prevention.
There is therefore a need for uniform application of the current recommendations 
designed  to  retard  the  progression  of  CKD; to  optimize  the  medical  management  of 
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comorbid medical conditions, such as cardiovascular disease, diabetes mellitus and lipid 
disorders; and to decrease the complications secondary to progression of CKD, including 
hypertension, anemia, secondary hyperparathyroidism, and malnutrition1.
Once the disease has progressed to CKD 5, patients have decreased quality of life, 
high morbidity, and an annual mortality of about 22%.
The  high  morbidity  and  mortality  seen  in  dialysis  patients  may  decrease 
significantly if patients were healthier at the time of initiating renal replacement therapy 
(RRT).
Data  from  India  is  lacking  on  how  patients  with  CKD  5  are  treated  in  the 
community. Data obtained about the pre-tertiary hospital care of patients with CKD 5 
would form the background to see the pitfalls in treatment and would allow us to address 
the problem better and provide better treatment to the patients who come to us for help.
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Consensus Definition
In  2000,  the  National  Kidney  Foundation  (NKF)  Kidney  Disease  Outcome 
Quality Initiative (K/DOQI) Work Group set about to develop clinical practice guidelines 
to define chronic kidney disease (CKD) and to classify stages in its  progression. The 
work  group  consisted  of  experts  in  nephrology,  pediatric  nephrology,  epidemiology, 
laboratory  medicine,  nutrition,  social  work,  gerontology  and  family  medicine.  An 
Evidence Review Team, consisting of nephrologists and methodologists, was responsible 
for assembling the evidence. 
Defining CKD and classifying the stages of severity would provide a common 
language for communication among providers, patients and their families, investigators, 
and policy-makers and a framework for developing a public health approach to affect 
care and improve outcomes of CKD. This would also permit more reliable estimates of 
the prevalence of earlier  stages of disease and of the population at  increased risk for 
development of CKD. From this would come recommendations for laboratory testing to 
detect earlier stages and progression. It was also possible to find associations of stages 
with clinical manifestations of disease.  
The  staging  of  CKD is  useful  because  it  endorses  a  model  in  which  primary 
physicians and specialists share responsibility for the care of patients with CKD. This 
classification also offers a common language for patients and the practitioners involved in 
the treatment of the disease.
Based  on  these  stages  of  CKD,  one  could  now  evaluate  treatments  to  slow 
progression or prevent other adverse outcomes. 
The Work Group defined CKD to include conditions that affect the kidney, with 
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the potential to cause either progressive loss of kidney function or complications resulting 
from decreased kidney function. 
CKD was thus defined as the presence of kidney damage or decreased level of  
kidney function for three months or more, irrespective of diagnosis. (Table 1)
Table 1 - Definition of Chronic Kidney Disease1
Calculation of Glomerular Filtration Rate (GFR)
An essential  requirement  for  the  classification  and monitoring  of  CKD is  the 
measurement or estimation of glomerular filtration rate (GFR). Serum creatinine is not an 
ideal marker of GFR, because it is both filtered at the glomerulus and secreted by the 
proximal tubule. Creatinine clearance (CrCl) is known to overestimate GFR by as much 
as 40% in normal individuals and by even more in patients with CKD2. 
Estimates of GFR based on 24-hour CrCl require timed urine collections, which 
are  difficult  to  obtain  and  often  involve  errors  in  collection.  Classic  methods  for 
measurements of GFR, including the gold-standard inulin clearance, are cumbersome, 
require  an  intravenous  infusion  and  timed  urine  collections,  and  are  not  clinically 
feasible. In adults, the normal GFR based on inulin clearance and adjusted to a standard 
body surface area of 1.73 m2 is 127 ml per minute per 1.73 m2 for men and 118 ml per 
minute per 1.73 m2 for women, with a standard deviation of approximately 20 ml per 
minute per 1.73 m2. After age 30, the average decrease in GFR is 1 ml per minute per 
1.73 m2 per year1.
Equations based on serum creatinine but factored for gender, age, and ethnicity 
are the best alternative for estimation of GFR. The most commonly used formula is the 
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Cockcroft-Gault equation3. This equation was developed to predict CrCl, but has been 
used to estimate GFR.
CrCl = [(140-age) x Weight (Kg)]/[S. Cr x 72]   [x 0.85 in women]
The Cockcroft–Gault  formula is  reasonably accurate  in mild renal  impairment  with a 
GFR of around 50 ml/min but can overestimate GFR by up to 100 per cent when GFR is 
less than 10 ml/min. 
The Modification of Diet in Renal Disease (MDRD) Study equation was derived 
on the basis of data from more than 500 patients [using the clearance of Iothalamate] with 
a wide variety of kidney diseases and GFRs up to 90 ml per minute per 1.73 m2. The 
abbreviated MDRD equation4,5  is recommended for routine use and requires only serum 
creatinine, age, gender and race.
GFR = 186.3 x (S. Cr)-1.154 x (age)-0.203 x (0.742 if female) x (1.21 if black)
This  formula  is  more  accurate  especially  at  low  clearance  and  in  preferred  to  the 
Cockcroft-Gault method. A caveat is that this method has only been validated in Black 
and White Americans and not in other racial groups. 
Why “Kidney”? 
The word “kidney” is of Middle English origin and is immediately understood by 
patients, their families, providers, health care professionals, and the lay public of native 
English speakers. On the other hand, “renal” and “nephrology,” derived from Latin and 
Greek roots, respectively, commonly require interpretation and explanation. 
Classification of CKD
Table 2 shows the classification of stages of CKD, including the population at 
increased risk of developing CKD, and suggested actions to prevent the development of 
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CKD and to improve outcomes in each stage. 
Table 2 - Classification of Chronic Kidney Disease
The  shaded area  identifies  patients  who  have  CKD.  The  unshaded  area  designates 
individuals who are at increased risk for developing CKD. 
Kidney  damage  is  defined  as  pathologic  abnormalities  or  markers  of  damage,  
including abnormalities in blood or urine tests or imaging studies.
* Includes actions from preceding stages.
Adverse outcomes of CKD are based on the level of kidney function and risk of 
loss of function in the future. It has almost been a uniform observation that CKD tends to 
worsen  over  time.  Therefore,  the  risk  of  adverse  outcomes  increases  over  time  with 
disease  severity.  Many  disciplines  in  medicine,  including  related  specialties  of 
hypertension,  cardiovascular  disease,  diabetes,  and  transplantation,  have  adopted 
classification  systems  based  on  severity  to  guide  clinical  interventions,  research,  and 
professional  and  public  education.  Such  a  model  is  essential  for  any  public  health 
approach to disease. 
The extent of the problem and Epidemiology of CKD
Chronic  kidney  disease  is  a  worldwide  public  health  problem  with  rising 
incidence and prevalence of kidney failure, with poor outcomes and high cost. Data from 
the United States suggests that the incidence and prevalence of CKD 5 have doubled in 
the past 10 years and are expected to continue to rise steadily in the future. 
The  third  National  Health  and  Nutrition  Examination  Survey  (NHANES  III: 
1988–1994) estimated that 3% of the population of the United States of America (USA) 
(5.6 million individuals) had an elevated serum creatinine (1.4–1.6 mg/dl)6. About 12% 
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of the population has a GFR of less than 60 ml/min.
Figure 1 (given below) shows the incidence and prevalence of CKD 5 in  the 
United States based on the USRDS 2000 Annual Data Report7. Incident patients refers to 
new cases during the year. Point prevalent patients refers to patients alive on December 
31st of the year. Projections for future years are based on extrapolation of regression 
equations. 
Figure 1 - Incidence and prevalence of CKD 5 in United States 
Data from the USRDS 2000 Annual Data Report
 
In  the  United  Kingdom  (UK),  the  prevalence  of  renal  impairment  (serum 
creatinine of >1.36mg/dl) was 6.1% in known hypertensives, 12.6% in known diabetics 
and 16.9% in patients with both these conditions in the age group 50–75 years8.  It  is 
estimated  that  the  dialysis  population  will  double  in  the  next  15  years  consisting 
predominantly of  elderly patients  with  diabetes  mellitus  and hypertension.   All  these 
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patients were detected by routine screening in a primary health care setting. 
In developed countries like USA and UK, most patients are sent in a stable state 
to the renal outpatient clinic. At the first visit a thorough medical history and physical 
examination are obtained and the patient's previous case records are carefully scrutinized. 
Additional  investigations are  carried out to fill  in  the gaps.  Thus,  a diagnosis  can be 
established and decisions about management may be made. Some patients present as an 
'acute  uraemic  emergency'  with  a  short  history  and  no  diagnosis;  they  are  first 
resuscitated and then investigated to detect or exclude an acute renal condition which will 
require specific treatment. Thereafter, establishing a diagnosis can proceed at leisure in 
those countries.
Epidemiology of Chronic Kidney Disease in India
Similar date regarding epidemiology of CKD is unavailable in our country. There 
are only two population based studies from India to date. The first study was from Apollo 
Hospital, Chennai by Dr. M. K. Mani.9 Prevalence of CKD in the surveyed community 
was 0.16% and other renal diseases (short of CRF) in 0.7% of patients. However, all the 
patients were not evaluated with blood tests for urea and creatinine, and only those who 
had some abnormality in the urine test or blood pressure and/or a positive response to a 
questionnaire were subjected to a blood test for urea and creatinine.
The second study was from All India Institute of Medical Sciences by Dr. Sanjay 
Agarwal10. This was a community based study done in urban Delhi where 4972 subjects 
were screened with blood urea and serum creatinine estimation with a specific aim to find 
out the prevalence of CKD. The prevalence of CKD, defined as serum creatinine > 1.8mg
% persisting for more than 3 months in the absence of any reversible factor, was found to 
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be 0.79% or 7852 per million population. Extrapolating the estimate of the number of 
CKD 5 to be 10% of this number, the prevalence is about 785 per million population in 
India. 
Clinical Features and Investigations in Chronic Kidney Disease
When the patient presents with CKD and is referred early in the course of the 
disease,  the need for a diagnosis  is  self-evident.  The difficulty of obtaining a precise 
diagnosis  increases  as  the  patient  approaches  CKD  5  and  the  rewards  diminish. 
Consequently, a substantial proportion of patients starting dialysis have no more precise a 
diagnosis than 'CKD – native kidney disease - unknown'.
Although it is virtually impossible to establish a firm diagnosis in some patients 
presenting  in  CKD 5 with  small  fibrotic  kidneys,  it  is  prudent  to  pursue  a  vigorous 
diagnostic approach in all others, since a precise diagnosis is invaluable in identifying the 
groups of diseases causing CKD which affect patient management. 
Etiology of Chronic Kidney Disease
Renal insufficiency can ensue from a primary renal disease or a systemic disease 
which affects the kidneys. 
Renal causes
 
Glomerulonephritides
These manifest as haematuria, signs of a nephrotic syndrome (tiredness, weight 
gain,  oedema,  susceptibility to  infection,  hyperlipidaemia),  and/or  hypertension.  With 
more  frequent,  regular  health  screening,  one  of  the  most  common  presentations  of 
chronic glomerulonephritis (e.g. IgA nephropathy) is the detection of dipstix proteinuria 
(and/or haematuria), hypertension and/or elevated serum creatinine in an asymptomatic 
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patient. 
Reflux nephropathy
Usually  diagnosed  in  childhood  during  investigation  of  urinary  infection  or 
screening  in  families,  it  may,  however,  escape  discovery  until  adult  life  when  it  is 
detected during investigation of urinary infection, especially in pregnancy, hypertension, 
or renal failure. Though often silent, there may be a history of recurrent episodes of flank 
pain, dysuria, fever, and rigors. CKD in adult life peaks in the twenties and thirties and is 
uncommon after the age of 50. 
Secondary chronic pyelonephritis
This  is  the  etiology  in  patients  with  CKD  and  a  history  of  stone  disease, 
obstruction, or neuropathic bladder. 
Medication related 
Both over the counter as well as prescribed and recreational drugs are implicated 
in  this  category.  Chinese  herb  nephropathy  (caused  by  Aristolochia  fangchi)  is  an 
example where fibrosis and tubulointerstitial changes persist for months or years after 
discontinuation of the toxin though slow recovery may occur on stopping.  Prolonged 
consumption of non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 
agents has also been implicated in the etiology of CKD (analgesic nephropathy). These 
drugs also cause a reduction in GFR in patients with glomerulonephritis, due to inhibition 
of  vasodilatory  prostaglandins,  acute  interstitial  nephritis,  nephrotic  syndrome  or 
papillary necrosis.  Angiotensin-converting enzyme (ACE) inhibitors and/or Angiotensin 
II Receptor Blockers may cause renal insufficiency in patients with bilateral renal artery 
stenosis or renal artery stenosis in a single kidney due to renal hypoperfusion. 
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Hereditary nephritis
Autosomal Dominant Polycystic Kidney Disease (APKD) is the most frequent 
cause of CKD in hereditary nephritis. Renal failure usually occurs in the third to fifth 
decade; family history is positive in ~ 75% cases. Similarly, a positive family history is 
usual in the rarer types of renal cystic disease such as tuberous sclerosis and medullary 
cystic disease. Alport's syndrome is another important hereditary nephritis characterized 
by progressive nephritis with haematuria and sensori-neural hearing loss. 
Infections 
Renal  tuberculosis  is  a  rare  cause  of  CKD.  Classically,  the  presentation  is  of 
dysuria,  fever and sterile pyuria and is  confirmed by urine culture and renal imaging 
(calcified renal substance). Interstitial renal tuberculosis causing renal failure with small 
kidneys on imaging and without the tell-tale renal calcification is diagnosed by renal 
biopsy or inferred from evidence of tuberculosis  in other systems.  Another infection 
associated with CKD 5 that shows a geographic variation is schistosomiasis which is an 
important cause in Egypt. 
Substance abuse 
Heroin-associated nephropathy (was an important cause of CKD 5 in New York)
Systemic diseases
Diabetes mellitus
Diabetes mellitus is the most frequent cause of renal involvement in a systemic 
disease.  Renal  involvement occurs  as frequently in type II  as in  type I  diabetes.  The 
increasing  prevalence  of  CKD in  the  developed world  in  particular  is  predominantly 
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accounted for by type II  diabetic  nephropathy11.  Hence,  the need for good control  of 
blood sugars to prevent microalbuminuria and therafter ACE inhibitors and/or ARBs to 
retard progression.
Hypertension
Long-standing  'benign'  hypertension  is  also  an  important  cause  of  CKD, 
particularly in the elderly age group, but is difficult  to differentiate from occult renal 
diseases with secondary hypertension except by renal biopsy. 
Systemic Lupus Erythematosus (SLE)
A diagnosis of SLE may be initially suspected clinically and then a renal biopsy is 
done to assess the severity of renal illness or else it is diagnosed when a renal biopsy is 
performed in any patient with proteinuria or abnormal urinary sediment. Therefore most 
patients should have one at the time of their initial assessment for renal insufficiency. 
Amyloidosis
Secondary  amyloidosis  is  suspected  when  CKD  complicates  long-standing 
inflammatory diseases (like severe rheumatoid arthritis) or chronic infections (such as 
destructive lung tuberculosis). It presents as a nephrotic syndrome. Primary amyloidosis 
occurs due to the proliferation of a single clone of plasma cells in middle and old age 
presenting  with  renal  insufficiency  and  proteinuria.  In  patients  with  plasma  cell 
dyscrasias,  renal  failure  may also result  from myeloma cast  nephropathy,  light  chain 
deposition disease or hyperviscosity syndrome. 
Systemic vasculitis and Anti-glomerular basement membrane disease
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Systemic  vasculitis  and  Anti-glomerular  basement  membrane  disease  usually 
present  as  rapidly progressive  renal  failure.  A history of  haemoptysis  and  dyspnoea, 
together with rapidly deteriorating renal function and an active urine sediment, suggest 
antiglomerular basement membrane disease (Goodpasture's syndrome) but can also occur 
in  systemic  vasculitis.  Other  significant  symptoms  are  of  persistent  sinusitis  with 
dyspnoea,  cough,  and  haemoptysis  (Wegener's  disease)  or  only  systemic  symptoms 
(microscopic polyangitis).
Thrombotic microangiopathy
This  may  occur  due  to  haemolytic  uraemic  syndrome,  thrombotic 
thrombocytopenic purpura or anti phospholipids antibody syndrome.
Occupational renal diseases
 Occupational renal  diseases causing CKD is an extremely rare  entity with the 
exception of lead toxicity. Theses patients have hyperuricaemia, hypertension and small 
kidneys.  The  diagnosis  is  best  made  by  demonstrating  an  increase  in  urinary  lead 
excretion  following  an  infusion  of  EDTA.  More  recently,  long-term occupational  or 
environmental exposure to relatively low levels of cadmium has been shown to cause 
CKD12. 
Postrenal causes 
Prostatic hypertrophy
 This presents with obstruction of the lower urinary tract is common in elderly 
males and is usually symptomatic. However, 40 per cent of men over the age of 65 have 
some of the symptoms of hesitancy, slow and forked stream, urgency with or without 
urge incontinence, frequency, intermittency, nocturia, and terminal dribbling13. Pressure-
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flow measurements have shown that two-thirds of these patients have some degree of 
outflow obstruction and are at risk of urinary retention14. A useful clinical clue to serious 
outflow obstruction is palpation of a distended bladder after micturition (confirmed more 
reliably by ultrasonography before and after micturition). 
Other  causes  of  obstruction  are  retroperitoneal  fibrosis,  sloughed  papillae  and 
renal calculi inducing hydronephrosis and a deterioration of renal function. 
Clinical examination 
At the patient's first visit, although a full standard physical examination, as taught 
during undergraduate medical studies is recommended, it  is  seldom practiced in busy 
outpatient  clinics.  The  common clinical  findings  in  practice  are  of  anemia  and fluid 
overload. Other occasionally found features are those of overt uremia such as asterixes or 
pericardial rub. Abdominal examination alerts the clinician to the presence of palpable 
kidneys (in ADPKD or hydronephrosis) or palpable bladder in bladder oulet obstruction. 
Rarer findings are of clues such as the body habitus of Lawrence Moon Biedl 
syndrome (a  rare  cause of CKD), a  saddle  nose (in  Wegener's  disease),  deafness (in 
Alport's disease) and skin manifestations of Systemic Lupus Erythematosus. Per rectal 
examination  may  reveal  an  enlarged  prostate  or  a  pelvic  mass  causing  urinary 
obstruction. The neurological examination may detect the neuropathies associated with 
diabetes, vasculitis and and primary amyloidosis. Fundus examination (through a dilated 
pupil) shows presence of retinal haemorrhages and exudates. There may also be corneal 
calcification, pingueculae or rarely the 'uraemic red eye' of acute hypercalcaemia usually 
precipitated by overdose of vitamin D analogues.
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Laboratory investigations 
After history and clinical examination, the relevant investigations (urine, blood, 
radiology and histology) are to be done to confirm the diagnosis.
Urine 
Urinalysis and microscopy
Dipstick examination of a fresh mid-stream urine sample is useful to assess the 
urinary pH and screen for leucocyturia, proteinuria, haematuria, and glucosuria. The pH 
is  usually low in CKD, unless the patient is  on a very low protein diet.  If  the urine 
contains non-albumin proteinuria, then the dipstick test will be negative with the 24-hour 
quantification showing significant proteinuria. 
Microscopy  of  the  urine  sediment  may  reveal  erythrocytes  (dysmorphic  if 
glomerular  in  origin),  leucocytes  and  casts.  Erythrocyte  casts  are  seen  in 
glomerulonephritis (IgA, postinfectious, and SLE) and in cases of vasculitis. Leukocyte 
casts  identify  pyuria  as  coming  from  the  kidney  and  are  found  in  stone  disease, 
tuberculosis, analgesic nephropathy and other causes of chronic interstitial nephritis. 
Quantitation of proteinuria (24-hours) 
Quantitation of proteinuria (24-hours) is used to measure proteinuria. Proteinuria 
is almost universal in CKD with the proteinuria in the nephrotic range in conditions like 
diabetic  nephropathy.  The accuracy of  the collection is  checked by quantitating  total 
urinary creatinine, which is fairly constant (range 10–14 mmol/day in females and 12–18 
mmol/day in males). The degree of proteinuria can be also be “measured” by the spot 
urine protein/creatinine ratio and a good correlation has been shown between the two 
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measures,15 although  the  accuracy  decreases  at  extremes  of  creatinine  excretion  (e.g. 
muscular  men who have  high and cachextic  patients  who and low urinary creatinine 
concentrations, respectively). 
Blood 
Hematology
A full hemogram is important to establish the type of anaemia in a patient with 
CKD. A Coomb's test  is  done if  clinically indicated to  exclude autoantibody-induced 
haemolysis (as can occur in SLE). A peripheral blood smear may show microangiopathic 
haemolytic anaemia (fragmented and helmet-shaped erythrocytes and burr cells). If this 
occurs in combination with thrombocytopenia, it is suggestive of the haemolytic uraemic 
syndrome or thrombotic thrombocytopenic purpura. 
Biochemistry
Serum creatinine concentration provides only a rough approximation of GFR as 
the amount excreted increases with a decline in GFR16.
The electrolyte profile shows the presence of hyperkalemia and severe metabolic 
acidosis.  Blood  sugar  estimation  and  liver  function  tests  provide  information  about 
underlying diseases such as diabetes mellitus and liver failure. 
Serology 
Serological tests can give additional support in the assessment of a diagnosis and 
underlying disease activity. Serum total haemolytic complement and C3 can be decreased 
in  mesangiocapillary  glomerulonephritis,  postinfectious  glomerulonephritis  (including 
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endocarditis),  cryoglobulinaemia  and  lupus  nephritis.  Elevated  titres  of  serum  anti-
nuclear  antibody and  anti-double-stranded  DNA support  the  diagnosis  of  lupus.  In  a 
patient  with  rapidly  progressive  renal  failure  with  an  active  urine  sediment, 
antiglomerular  basement  membrane  antibodies  confirm  a  diagnosis  of  Goodpasture's 
disease while Anti-Neutrophil Cytoplasmic Antibodies support a diagnosis of systemic 
vasculitis  (Anti-proteinase  3  -  specific  for  Wegener's  granulomatosis  or  Anti-
myeloperoxidase - associated with microscopic polyangitis). 
Virology 
Patients  with  CKD  are  commonly  tested  for  antibodies  against  Human 
Imunodeficiency Virus  (HIV)  and  Hepatitis  C Virus  (HCV) and Hepatitis  B  surface 
antigen  (HBsAg).  HBsAg  is  associated  with  membranous  glomerulopathy,  IgA 
nephropathy  and  mixed  cryoglobulinaemia.  HCV infection  is  associated  with  type  1 
membranoproliferative glomerulonephritis and cryoglobulinaemia. About 95 per cent of 
patients  with mixed essential  cryoglobulinaemia have evidence of HCV infection (by 
testing for anti-HCV antibodies and HCV RNA). 
Knowing the virology status is also important in vaccinating against Hepatitis B 
virus to protect against infection from dialysis and blood transfusions.
Radiological investigations 
Renal ultrasonography is invaluable in assessment of a patient of CKD. The renal 
size, renal cortical thickness and echogenicity can be determined. The presence of cysts 
and  hydronephrosis  can  be  demonstrated.  If  calculi  are  suspected,  plain  x-ray of  the 
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urinary tract can be done followed by intravenous urography (if renal function is normal) 
or non-contrast spiral computerized tomography (CT).  CT with intravenous contrast and 
arteriography  (or  magnetic  resonance  imaging  with  angiography)  is  required  for 
diagnosis  of  classical  polyarteritis  nodosa  and  renovascular  disease.  However, 
angiogaphy remains the 'gold standard' for diagnosing renovascular disease.
Role of biopsy 
In  places  where  routine  health  checks  are  commonplace  or  if  the  patient  has 
presents  early  in  the  course  of  the  illness,  a  renal  biopsy is  mandatory (in  most)  to 
establish a diagnosis, to assess the extent of damage and to plan therapy. In others, it may 
have  been  deemed  unnecessary  because  the  diagnosis  was  established  on  clinical 
grounds, for example, in diabetes. If the kidneys are small, the hazards of the procedure 
are increased and have to be weighed against the small chance of finding a reversible 
cause. 
Establishing chronicity in CKD
In a patient with no prior medical illness presenting with renal impairment, it is 
necessary to establish chronicity based on clinical and laboratory evidence.
The factors that suggest chronicity are: 
• Duration of symptoms for several months
• Nocturia
• Absence of severe symptoms despite very high urea and creatinine
• Anaemia of chronic disease
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• Bone disease 
• Sexual dysfunction 
• Skin disorders, nail changes and pruritus
• Neurological complications 
• Small kidneys on renal imaging
Treatment of CKD
Attenuation of progression 
Once a diagnosis of CKD is made, there are certain medical measures that can be 
undertaken to attenuate the progression.
Blood pressure control 
The importance of the control of blood pressure in patients with renal disease 
cannot be overemphasised. Hypertension is common in patients with CKD and the rate of 
decline in renal function increases with increasing blood pressure17,18 and also reduction in 
blood  pressure  attenuates  the  deterioration  of  renal  function  (first  convincing 
demonstration was in diabetic nephropathy).19,20
Two important factors contribute to the rise in blood pressure of patients with 
CKD. First, most renal diseases are associated with sodium retention, which results in an 
increase in extracellular fluid volume and an increase in peripheral vascular resistance. 
Second,  activation  of  the  renin–angiotensin–aldosterone  system  results  in  increased 
circulating  angiotensin  II,  which  in  addition  to  being  a  potent  vasoconstrictor,  also 
enhances sodium retention by the kidney. Hence, the two initial steps in the treatment of 
hypertension in CKD should consist of a reduction in sodium intake, with or without the 
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use of diuretics, and treatment with agents that block the effects of angiotensin II, that is, 
ACE inhibitors  or  ARBs.   Other  antihypertensives  that  are  commonly prescribed  are 
calcium  channel  blockers,  beta  adrenergic  antagonists,  α-adrenoceptor  blockers  and 
diuretics.
The target blood pressure in patients with CKD is 120/70 mmHg especially with 
proteinuria of over 1 g/day21,22. Regular follow-up is essential as it has been demonstrated 
that patient compliance, efficacy of antihypertensive treatment, and retardation of renal 
failure are clearly related to the number of outpatient visits23. 
Dietary recommendations
Sodium restriction
In patients with CKD, the ability to excrete sodium usually is limited. Thus, a 
sodium-restricted diet of 6 g/day is a useful initial step in the treatment of hypertension. 
Determining a 24 h urinary sodium excretion can check compliance with the sodium 
restricted diet. 
Sodium depletion may occur in patients with CKD due to tubulointerstitial disease 
such as pyelonephritis, interstitial nephritis or hydronephrosis. In these, sodium has to be 
monitored closely and often restriction is not advisable.
Protein restriction
The initial observations in the rat model with reduced renal mass had shown that 
protein  restriction  attenuated  the  development  and  progression  of  renal  failure. 
Thereafter, some retrospective studies and several (but not all) randomized prospective 
studies confirmed that a low protein diet might have the same effect in humans. In the 
initial analysis of the Modification of Diet in Renal Disease (MDRD) Study,4 (which was 
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the largest trial to date on the effect of protein restriction on CKD in man) the effects of 
dietary protein restriction and blood-pressure control  on the progression of CKD, the 
investigators reported a small beneficial effect of the low-protein diets on the course of 
renal function after an average follow-up period of 2.2 years. When the initial 4 months 
of  low-protein  diet  were  excluded from the  analysis,  the  decline  in  GFR of  protein-
restricted patients was attenuated24. This secondary analysis of the MDRD trial patients 
also revealed a high protein intake was associated with a more rapid decline in GFR. It 
was calculated that each 0.2 g/kg body weight reduction in protein intake resulted in a 29 
per cent reduction in the rate of decline in GFR. 
The effect of protein restriction on the progression of CKD has been analysed in 
two meta-analyses.25, 26 
Altogether, it can be concluded from these studies that protein restriction causes a 
modest reduction in the progression of CKD in man. It was concluded that dietary protein 
restriction significantly reduced the risk for renal insufficiency or death with a relative 
risk  of  0.67  (95% confidence  interval  0.50–0.89)  in  patients  with  non-diabetic  renal 
failure  and  0.56  (95%  confidence  interval  0.40–0.77)  in  patients  with  diabetic 
nephropathy.  Currently,  mild  protein  restriction  to  0.6  to  0.8  grams  per  kg  is 
recommended. Calorie intake is kept at 30 kcal/kg body weight/day or more.
Dietary protein  restriction  also helps  to  alleviate  the  symptoms of  uraemia  in 
those not being considered for dialysis in addition to attempting to slow the progression 
of  renal  insufficiency  without  negatively  jeopardizing  nitrogen  balance.  Dietary 
compliance is  monitored most readily by measuring the serum urea :  creatinine ratio 
(which  should  be  reduced  by  treatment)  and  the  24-h  urinary  urea  excretion.  For 
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example, a 40 g protein diet should produce about 150 mmol of urea. 
Fluid balance
In  CKD, the regulatory capacity of  the  kidney is  progressively reduced.  Both 
excretion and conservation of electrolytes and water are impaired; when sudden loads of 
potassium, acid,  or fluid has to be handled the limitations of renal functional reserve 
become  apparent  and  signs  of  decompensation  may  occur.  Consequently,  water  and 
electrolyte intakes must be adapted to renal excretory capacity. 
In the subset of patients who are fluid overloaded, both sodium and water have to 
be restricted. On the other hand, in patients with conditions that predominantly affect the 
renal medulla (for example,  interstitial  nephritis and pyelonephritis),  defective urinary 
concentrating ability is particularly common and dehydration occurs easily in patients 
with inadequate fluid intake, due to persistent diuresis despite fluid deprivation. Several 
mechanisms are responsible for the inability to excrete concentrated urine, including the 
increased solute load in remnant nephrons resulting in an osmotic diuresis, alteration of 
medullary interstitial  solute  concentrations  as  a  result  of  the  damaged  countercurrent 
exchange system and impaired medullary blood flow. In addition, impaired sensitivity to 
antidiuretic  hormone  causes  decreased  outward  water  transport  in  the  distal  nephron 
segments. As a result of decreased concentrating capacity, urine osmolality is roughly 
that  of  plasma,  approximately  300  mOsm/kg  H2O,  in  patients  with  CKD.  If  the 
obligatory osmolar  production  in  an  adult  is  around 600 mOsm/kg  H2O, daily  urine 
output will be roughly 2 l per day. Fluid intake should therefore be approximately 2–3 
l/day in order to ensure adequate urine flow rates and to prevent dehydration. In some 
patients who are 'salt losers', fluid requirements may be even greater. 
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Potassium
Patients with CKD are usually able to maintain serum potassium within normal 
limits until oliguria occurs or GFR is less than 5 ml/min. Preservation of normokalaemia 
results  from  an  adaptive  increase  in  potassium  excretion  by  remnant  nephrons  and 
increased bowel loss. However, hyperkalaemia may be an early feature of renal failure in 
patients  with  hyperchloraemic  metabolic  acidosis  and  hyporeninaemic 
hypoaldosteronism,  which occur  particularly in  patients  with chronic  tubulointerstitial 
nephritis and diabetic nephropathy. Hyperkalaemia also complicates an acute potassium 
load (e.g. blood transfusion, or medication, which interferes with potassium secretion, for 
example, potassium sparing diuretics, ACE inhibitors, β-blockers, and NSAIDs) Foods 
containing high levels of potassium like nuts, chocolate, fruits, wine and fruit juice and 
salt substitutes (containing potassium) are particularly dangerous. Therefore a judicious 
restriction  of  potassium rich  diet  and  monitoring  of  serum potassium while  on  ACE 
inhibitors and ARBs is warranted.
Other medications
Phosphate binders and calcitriol
Skeletal  abnormalities  occur  early  in  renal  failure,  well  before  symptoms 
develop.27 A variety of biochemical and radiological investigations are available to assist 
in  the  diagnosis  and  monitoring  of  renal  osteodystrophy of  which  serum parathyroid 
hormone  (PTH)  remains  the  single  most  useful  biochemical  test  in  predicting  bone 
histology in an individual patient.28
In early CKD, it would appear that adynamic bone disease is the principal type of 
bone  lesion  with  high  turnover  bone  disease  developing  with  more  advanced  renal 
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failure. As renal insufficiency progresses, higher levels of PTH are necessary for normal 
bone remodeling. The cause of this 'skeletal resistance' to PTH in uraemia is probably 
multifactorial.  Inhibition  of  osteoclastic  bone  resorption  appears  to  be  the  central 
mechanism. Therefore a plasma PTH of two to three times the normal value is usually 
required to maintain normal bone turnover. 
When the patient is seen in the early phases of CKD, the objective is to maintain 
normal bone turnover by maintaining serum calcium, phosphate, PTH and calcitriol and 
blood pH in the normal range. 
The mainstay in preventing secondary hyperparathyroidism is strict phosphorus 
control. Some dietary phosphate restriction is usually required once GFR is less than 50 
ml/min.  Care  must  be  taken in  maintaining a  sufficient  protein intake,  however,  and 
adequate nutrition must be maintained. Dietary restriction alone is usually inadequate in 
controlling serum phosphate once GFR is less than 25 ml/min. Phosphate binders are then 
added  to  reduce  phosphorus  absorption  from  the  intestine.  Calcium  carbonate 
(500-2000mg thrice daily)  is  effective and probably the most  widely used  phosphate 
binder. It must be taken with food to give optimal phosphorus binding and to reduce the 
risk of hypercalcaemia. If hyperphosphataemia persists despite administration of calcium 
carbonate, excess dietary intake (e.g. dairy products) should be excluded and alternative 
phosphorus  binding  agents  substituted.  Another  commonly  used  calcium  containing 
binders is calcium acetate. It is a more effective binder than calcium carbonate and is less 
likely to be associated with hypercalcaemia. The downside of using calcium containing 
phosphate binders is the risk of a positive calcium balance which in dialysis patients is 
associated  with  vascular  calcification  and  a  raised  calcium  x  phosphate  product  is 
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associated  with  a  higher  relative  risk  of  death.  In  the  face  of  hypercalcemia,  other 
phosphate binders like sevelemar hydrochloride and lanthanum carbonate may need to 
replace calcium based products.  Others still  being evaluated include polynuclear  iron 
preparations. 
In some patients, aluminium-containing phosphate binders have to be resorted to. 
If  needed,  they should be used only for  a  limited period of time since aluminium is 
absorbed to a variable extent and can lead to aluminium overload, manifesting as anaemia 
and aluminium-mediated bone disease. 
In patients with lower stages of CKD, administration of 1,25-(OH)2 D3 (calcitriol) 
0.25 μg/day causes a rise in  serum calcium, a fall  in  serum phosphorus and alkaline 
phosphatase, and retards the development of histological bone abnormalities.29
Careful  monitoring  of  serum  calcium  is  required,  since  hypercalcaemia  may 
accelerate the decline in renal function. Though new vitamin D metabolites are available 
such  as  22-oxacalcitriol,  paracalcitriol  (19  nor-1,25  dihydroxy-vitamin  D2),  and 
doxercalciferol (1-hydroxy-vitamin D2), their benefits over conventional calcitriol and 
alfacalcidol remain to be established30.  Bone biopsy is generally reserved for patients 
with unusual biochemical and radiological evidence of bone disease. 
Treatment of anemia
Anaemia  is  a  predictable  consequence  of  CKD  and  is  directly  related  to  its 
severity.  It  frequently occurs  early with one  study reporting  a  prevalence  of  45% in 
patients  with  a  serum  creatinine  ≤ 2  mg/dl31  Monitoring  anaemia  is  important  to 
determine if it becomes disproportionate to the stage of CKD. A haemoglobin of less than 
6 g/dl is rarely due to CKD alone. Red cell indices should be scrutinized to detect the 
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onset of iron, folate or vitamin B12 deficiency.  Functional iron deficiency is common 
and should be confirmed by measurement of percentage of hypochromic red cells, serum 
iron, transferrin and ferritin. As oral iron is often poorly tolerated, intravenous iron is 
now frequently administered to predialysis patients. Occult gastrointestinal bleeding is 
common  in  patients  with  advanced  stages  of  CKD  and  is  most  commonly  due  to 
superficial upper gastrointestinal lesions32. 
Recombinant human erythropoietin (rhEPO) is effective in treating anaemia in 
adults and children with CKD both prior to and while on dialysis. Benefits of correcting 
anaemia include increased quality of life, reduced morbidity and improved survival. This 
may be related to reduction in left ventricular mass and normalization of cardiac output 
with partial correction of anaemia. There is also evidence to suggest that rhEPO therapy 
may retard the progression of CKD and delay the onset of dialysis  by as much as 6 
months33, 34. 
Treatment of hyperlipidemia
Hyperlipidaemia is often present in patients with CKD35. Nonetheless, there are 
only a limited number of studies, usually with a small number of patients, in which the 
effects of treatment of hyperlipidaemia has been investigated. A meta-analysis by Freid et 
al  showed  clearly  that  treatment  of  hyperlipidaemia  ameliorates  the  progression  of 
CKD36, 37.
Other recommendations
Obesity is  clearly associated with hypertension,  and reduction of body weight 
should  be  recommended to  obese  patients.  Increasing  physical  exercise  and reducing 
calorie  intake  may  achieve  this.  In  patients  with  advanced  CKD,  caution  must  be 
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exercised in severe calorie restriction because of the risk of catabolism. 
Alcohol abuse can also contribute to hypertension and may also interfere with 
adherence to antihypertensive or other therapy. It is advisable to limit alcohol intake to 
less than 21 units in men and 14 units in women. 
In patients with CKD, it has been shown that cigarette smoking enhances the rate 
of progression of disease.38, 39 Thus, patients with CKD should be strongly advised to quit 
smoking.
Follow-up assessment and treatment 
The aims of follow-up are the following:
1. Monitor the progression to CKD 5 and slow or arrest it where possible; 
2. Detect and treat the complications of CKD and the primary disease; 
3. Detect those symptoms of uraemia that call for dialysis and transplantation; 
4. Plan and implement an orderly preparation for RRT. 
5. Timely vascular access or CAPD catheter placement to allow a smooth transition 
to dialysis
The ability to predict confidently the rate of progression of CKD is invaluable in 
making these plans. This is largely, though not exclusively, dependent on early referral to 
a  nephrologist40.  The  factors  most  likely  to  speed  progression  that  can  be  modified 
include control of blood pressure, diet,  avoidance of unnecessary drugs, and, in some 
instances, control of the underlying disease. Partial correction of anaemia with rhEPO 
may also slow progression. Care can be shared with the general practitioner in monitoring 
some of these parameters such as blood pressure. 
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Monitoring decline in GFR 
Serum creatinine concentration 
Serum creatinine is the most widely used serial  measurement of GFR but has 
important  limitations.  When  GFR  declines,  serum  creatinine  initially  changes  only 
slightly.41 (See Fig 2 below). Minor changes in serum creatinine may, therefore, reflect 
major changes in GFR. When the GFR declines to less than 40 ml/min/1.73m2, the loss of 
nephrons over-rides the effects of enhanced tubular secretion and decreased generation of 
creatinine, and large increases in serum creatinine correspond to small changes in GFR. 
Thus,  serum creatinine  concentration  is  a  poor  indicator  of  renal  function  in 
patients  with CKD and cannot  be used to  assess GFR accurately.  In  addition,  serum 
Figure 2
Relation  between  serum  creatinine 
and  GFR  in  171  patients  with 
glomerular disease.
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creatinine concentration is affected by other factors such as changes in muscle mass and 
nutritional status, physical activity and gut metabolism of creatinine42. 
Any reduction in serum creatinine in late CKD may well reflect a loss in muscle 
mass  rather  than  improvement  in  renal  function.  Another  more  suitable  endogenous 
marker for GFR is the protein cystatin C which is produced by all nucleated cells and 
which is almost exclusively eliminated from the circulation by glomerular filtration43. It is 
sowly being tried in in clinical practice. Its use has yet to become routine. 
Most clinicians use the Cockcroft–Gault formula but the MDRD formula being 
more accurate especially at low clearance is now preferred. 
Reciprocal of serum creatinine 
In every CKD patient on follow up, the reciprocal of the serum creatinine against 
time should be plotted.  Linear regression of this produces a straight line in most patients 
making it possible to predict the time when dialysis will be required. (See Fig 3).
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Figure 3 - The reciprocal plots of two patients with CKD on follow up 
illustrating a linear progression in decline in renal function
Several limitations of the reciprocal creatinine plot must be kept in mind. The 
accuracy of this prediction increases with the number of observations of serum creatinine. 
Also, a proportion of patients do not have a linear decline in renal function. Nine per cent 
of adults44  and 13 per cent of children45  deviated significantly from a straight line. Even 
among those that do follow a straight line, 20 per cent deviate from it at least once during 
their follow-up46.
However,  despite  these  limitations,  the  plot  is  useful  in  drawing  attention  to 
episodes  of  acute-on-chronic  kidney  disease,  monitoring  response  to  treatment,  and 
predicting when stage 5 will be reached. 
Preparing for RRT
Once the renal function is seen to be deteriorating, it is time to plan for RRT. A 
checklist is useful at this stage in the management of the patient. The check-list given 
below (Table 3) is one such list to ensure that all appropriate measures have been taken.
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From previous follow-up visits
Full blood count
Calcium, magnesium, 
phosphate
Liver function tests 
Alkaline phosphatase
Blood sugars
Other appropriate tests,
e.g. complement, VDRL, HBsAg, 
CRP,serum electrophoresis, HbA1C, 
24-h urinary protein
Midstream urine
Radiography
Renal ultrasound
ECG
Test Reason for test
In preparation for dialysis and transplant
Ferritin, iron, transferrin Iron status to look for concomitant iron deficiency
Folate and vitamin B 12 To rule out another cause of anaemia 
PTH, vitamin D To assess degree of renal osteodystrophy and as baseline 
Aluminium level As a baseline for dialysis and to assess toxicity 
Glucose tolerance test If fasting blood sugar is abnormal, to assess diabetic status 
HIV status If positive, will affect decisions regarding management. Special precautions with blood letting 
Hepatitis C status If positive, special precautions with blood letting 
Blood group, tissue typing 
and cytotoxic antibodies Relevant for future transplant 
Fasting lipids Patients are at risk of hyperlipidaemia 
CMV serology Relevant to future transplant and donor CMV serology 
Skeletal survey To assess renal osteodystrophy 
Micturating 
cystourethrogram 
A routine in some centres to assess the bladder and exclude 
reflux before transplant 
Dental assessment To look for occult dental sepsis pretransplant and for dental treatment predialysis 
Ophthalmology 
assessment In diabetics 
Urological assessment In certain conditions, e.g. reflux or stone disease 
Family planning In females of child-bearing age regarding contraception and in males for consideration of sperm banking 
Assessment by 
gastroenterologist 
It is routine in some centres to examine pretransplant 
patients by endoscopy 
Assessment by 
cardiologist For ischaemic heart disease 
Assessment by social To assess need for social support and counselling 
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worker 
Assessment by dialysis 
administrator To assess need for home adaptation for home haemodialysis 
Family interview For education and to assess possible family donors 
Assessment by dialysis 
nursing staff 
To assess suitability for CAPD/haemodialysis and 
counselling 
Table 3 Pre-renal replacement therapy assessment checklist
Social and psychological assessment 
Assessment of the patient's circumstances including distance from the nephrology 
clinic, cost and difficulty of travel determines the success of therapy. The occupational 
history is of great importance in judging the patient's suitability for the various types of 
RRT and the possible need for a change in occupation.  It is important to discuss and 
educate the patient with respect to all aspects of therapy including compliance to diet and 
medication, prognosis and the various aspects of RRT. Once the patient has moderate 
renal impairment, it is imperative to psychologically prepare him/her for RRT, especially 
if renal transplantation is planned.
The  patient  entering  a  dialysis  and  transplant  programme  has  to  face  many 
changes in life style due to such factors as dependence and change of body image. The 
patient must receive consistent and realistic advice about future treatment options. The 
renal unit should function as a multi-disciplinary team of which the social worker is a 
vital  member,  providing  the  social  assessment  on  which  many  decisions  hinge  and 
counseling the patient during an extremely stressful period. The social worker assesses 
the patient's grasp of what is happening and establishes good communication. This will 
depend on their intelligence, level of education, and linguistic skills. Also the patient’s 
family and social  relationships  and the  strength  of  these  support  systems  need to  be 
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assessed.  Their  housing is  important  in  deciding whether  peritoneal  dialysis  or home 
haemodialysis is a treatment option. Rehousing on medical grounds is a major issue even 
in  affluent  countries  and  usually  not  a  feasible  idea  in  our  country.  The  patient's 
employment record and financial situation are needed to be explored so that the RRT is a 
financially viable option. Interviewing the family is also part of the social assessment, 
giving a better understanding of the patient and his or her social inter-relationships and 
provides an opportunity to discuss the possibility of a live related transplant. 
Hepatitis screening
All patients should be screened for hepatitis B and C. Patients who are negative 
for HBsAg are to be offered vaccination if they do not have naturally acquired immunity. 
As CKD reduces the effectiveness of vaccination, it  is best to arrange this early. It is 
preferred  to  use  a  double  dose  schedule  of  the  Hepatitis  B  vaccine.  The  preferred 
injection site is the deltoid in adults and the anterolateral thigh in children because the 
buttock site is associated with a smaller chance of response. Approximately 75 per cent 
of subjects who are HCV antibody positive also have viral particles in their blood and are 
therefore  infectious.  In  them,  hepatitis  C  mRNA  should  be  sought.  Some  strains 
(genotype 1) are less responsive to treatment with interferon alpha. 
HIV testing 
It  is  advisable  to  test  for  HIV  infection  prior  to  dialysis  with  appropriate 
counselling when indicated. HIVAN is the third leading cause of CKD5 in Blacks in the 
age group 20–64 years after diabetes and hypertension in the United States47.  
The most likely mode of transmission to hospital staff is through inoculation of 
infected blood by needle prick and there is so far  no evidence of epidemic spread in 
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dialysis units. The majority of HIV infections are picked up by routine testing and if the 
patient is known to be HIV positive, continuous ambulatory peritoneal dialysis (CAPD) 
or home haemodialysis would be the treatment of choice in most cases. Blood taking 
should be kept to a minimum and special care should be taken in handling, transporting, 
and analysing samples. Healthcare workers need to be aware of the need for assessment 
for postexposure HIV prophylaxis in the event of a needle stick injury. 
Vascular access 
The  planning  of  vascular  access  is  of  great  importance  for  a  smooth  start  to 
haemodialysis. If a fistula is required for haemodialysis, it should be created at least 3 
months before the estimated date of starting dialysis in males and up to 6 months in a 
female  with  small  veins.  This  allows time for  maturation  of  the fistula,  prepares  the 
patient psychologically for the inevitable and avoids the need for temporary access such 
as a jugular or femoral vein catheter with all the attendant risks of such procedures viz 
trauma,  septicaemia,  venous  stenosis,  and  thrombosis.  Because  of  the  high  risk  of 
stenosis in the subclavian vein, which seriously jeopardizes future fistula attempts and 
venous hypertension in the fistula, the use of subclavian catheters should be avoided48.
Suitability for continuous ambulatory peritoneal dialysis 
During the predialysis assessment period, suitability for CAPD must be assessed. 
There  are  few  absolute  contraindications  to  CAPD  though  some,  such  as  a  major 
diaphragmatic  defects  will  only  become  apparent  after  CAPD  has  been  started.  A 
colostomy,  ileostomy,  or  nephrostomy is  a  firm contraindication  and previous  major 
abdominal operations form relative contraindications. For young children, for those with 
severe  physical  handicaps  such  as  blindness,  crippling  arthritis,  paralysis,  or  severe 
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incoordination and for the mentally handicapped a family member such as the spouse or 
parent will  be trained, and thus the suitability of the helper will need to be assessed. 
However,  blind patients  and some with severe arthritis  have been trained to  perform 
CAPD successfully themselves. 
Obesity and hyperlipidaemia get worse more frequently in CAPD patients than in 
haemodialysis patients, so they are a relative contraindication to CAPD. Abdominal wall 
hernias are aggravated by CAPD and should be repaired before CAPD is started. CAPD 
will also result in an exaggerated lumbar lordosis, and if pre-existing lumbar disc disease 
is present, this will almost always deteriorate on CAPD. 
Suitability for pre-emptive transplantation 
Pre-emptive renal transplantation, if contemplated, should obviously be planned 
early in the assessment of the patient. When possible, it obviates all the attendant risks 
and cost of dialysis. It is appropriate in patients with a predictable cause, such as diabetes, 
so that stage 5 can be accurately dated. It is also easier to plan when a family donor is 
available.  Interestingly,  pre-emptive  transplantation  compared  to  transplantation  from 
long-term dialysis is associated with better graft survival. In a study by Mange et al49, 
there was a 52 per cent reduction in the risk of allograft loss in the first year in patients 
who underwent renal transplantion without prior dialysis. 
Palliative care
Some patients approaching CKD 5 do not wish to have RRT and in others it may 
be inappropriate if multiple other comorbid conditions coexist. In such cases, providing 
good palliative care at the end of life is essential. Many symptoms can be alleviated with 
the use of drugs such as rhEPO and diuretics, analgesics, and later, sedatives. Frequently 
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nephrologists lack appropriate training in palliative care and a multidisciplinary approach 
should be adopted drawing on facilities such as the local hospice, district nurses, and 
general practitioners according to local circumstances. 
Monitoring uraemic symptoms and when to start RRT
Monitoring the patient to assess when dialysis will be required is one of the main 
aims of follow-up and one of the most difficult. The timing of the start of dialysis is 
controversial, not least because of financial and practical implications and consequently 
the practice varies widely. Recently there has been a general trend in the developed world 
to initiate dialysis at an earlier stage of renal failure which would be in line with the 
DOQI recommendations that dialysis should be commenced once the GFR declines to 
less than 10.5 ml/min/1.73 m2 or the creatinine clearance is in the range of 9–14 ml/min. 
This guideline is based on opinion only. The decision of when to start dialysis should 
involve a combination of clinical acumen in assessing symptomatology, discussed below, 
and identifying early signs of malnutrition in association with measurements of declining 
GFR discussed above. Evidence currently would also suggest that delaying dialysis till 
the GFR is less than 6 ml/min irrespective of symptoms is unsafe. 
The complaints of patients on starting dialysis (Malangone et al,)50 were: 
• anorexia–nausea–vomiting 76%
• fatigue-weakness 72%
• pruritus 40%
• dyspnoea-orthopnoea 26%
• insomnia 14%
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• bleeding tendency 14%
• apathy—mental changes 12%
• asterixis-muscle twitching-cramps 11%
• dysguesia 8%
The  authors  found  that  none  of  these  symptoms  had  a  significant  relationship  to 
biochemical measurements reflecting GFR (creatinine clearance, serum creatinine, and 
urea) except bleeding tendency. 
The  onset  of  pericarditis  or  symptomatic  peripheral  neuropathy,  with  no 
alternative explanation, is an indication that dialysis is already late and should be started 
at once. Nausea and vomiting are signs that dialysis is needed very soon. Restless limbs 
(a  symptom which  patients  have  difficulty  in  describing  and  often  refer  to  as  pain, 
itching, or discomfort until questioned closely) are usually a sign that dialysis is needed 
soon; a more generalized restlessness syndrome is an uncommon but dramatic indication 
that it is overdue. Severe pruritus and excoriated rash is an indication for early dialysis if 
not explained by drug allergy or coincidental skin disease. Other warnings that uraemia is 
becoming  troublesome  are  myoclonic  jerks  (particularly  on  falling  asleep),  sleep 
disturbance,  severe  lethargy,  mental  clouding,  loss  of  concentration  and  sexual 
dysfunction in younger adults, unexplained by drug therapy. In a significant minority of 
our patients, the trigger to starting dialysis is difficulty in controlling fluid balance and 
blood pressure rather than the symptoms or biochemical evidence of severe uraemia. A 
check for ankle oedema, crepitations at the lung bases, a raised jugular venous pressure 
and the presence of cardiomegaly, a third heart sound and functional cardiac murmurs is 
therefore a routine part of the follow-up assessment. 
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The  National  Kidney  Foundation-Dialysis  Outcomes  Quality  Initiative  (NKF-
DOQI)  guidelines  recommends  that  dialysis  is  initiated  when  the  nPNA (normalized 
protein catabolic rate (nPNA) falls to below 0.8 g/kg per day. This is a measure of the 
level of protein intake. 
The problem of late referral to nephrology services
Timely referral of patients with CKD to specialist nephrological care is needed to 
ensure the introduction of such measures early enough in the disease process to provide 
benefit. However, worldwide 30–40% of patients are referred to a nephrologist at a very 
late stage of renal disease.51, 52, 53, 54
In a study called “Late referral for dialysis: improving the management of chronic renal 
disease”,  Roderick  et  al  found  that  one  in  six  of  all  those  starting  RRT who  were 
avoidably late-referred, and might have benefited from earlier intervention under care of 
a nephrologists54.
Late referral is likely to result in the patients having a lower serum calcium and 
albumin and they were less likely to have a permanent vascular access in place at the start 
of dialysis. They were also more likely to have a hematocrit less than 28% and were less 
likely to have received Erythropoeitin55.Late referral has also been shown to influence 
early mortality56. 
In the United Kingdom, the Renal Association has recommended that all patients 
with serum creatinine > 150µmol/l (1.7mg/dl) be referred to a nephrologist57. While this 
might  be  an  extreme,  an  early  referral  once  the  diagnosis  of  CKD is  established  is 
advantageous. The patients can then be followed up on a regular basis by his personal 
physician with reviews with the nephrologist on a periodic basis and thus care can be 
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complementary.
 
Aim: 
To evaluate patients with Chronic Kidney Disease Stage 5 [CKD 5] regarding:
1. Their pre-tertiary hospital care and 
2. To assess their knowledge of the disease and its treatment
Objectives: 
1. To assess the pre-tertiary hospital care of consecutive patients with CKD 5 who 
presented themselves to the nephrology services of Christian Medical College, 
Vellore.
2. To  describe  the  demographic  profile,  education,  occupation,  socio-economic 
status,  previous  treating  personnel,  referral  pattern,  native  kidney  disease  (if 
known),  previously done  investigations,  vaccination  against  Hepatitis  B virus, 
treatment  received,  prior  patient  education  and  decision  towards  renal 
replacement therapy. 
3. To  determine  if  the  care  given  prior  to  coming  to  a  tertiary  hospital  was 
appropriate and whether early referral to a nephrologist improved the adequacy of 
treatment. 
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Study Design:
The study was a cohort study on pre-tertiary hospital care of consecutive patients 
with Chronic Kidney Disease stage 5 (CKD 5) who presented to the nephrology services 
of Christian Medical College, Vellore. 
Setting:
The  study  was  conducted  among  the  out-patients  of  the  Department  of 
Nephrology, Units I and II of the Christian Medical College (CMC), Vellore, South India 
which is a 1800 bedded tertiary care teaching hospital. Nephrology services have been 
offered here for over 3 decades. 
Subjects
Inclusion Criteria: 
a. Subjects  were  newly  diagnosed  cases  of  CKD  5  based  on  history,  calculated 
glomerular filtration rate less than 15ml/min (by the Modification of Diet in Renal 
Disease formula) 
b. They had compatible ultrasonographic evidence of CKD 5.
Exclusion Criteria:
a. The study excluded subjects who had been diagnosed to have CKD at CMC prior to 
the study period.
b. The study excluded the cases of renal insuffiency where the diagnosis of chronicity 
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was in doubt and required verification by further investigations.
Evaluation: 
Consecutive pts with CKD 5 presenting to Nephrology services (over an eight 
month period) were prospective enrolled upon making a diagnosis of CKD 5. Both the 
patient  and his  relatives were interviewed by the investigator with regard to  the pre-
tertiary  hospital  management.  The  data  thus  collected  was  then  entered  into  an 
electronically compatible proforma. 
Statistical Analysis:
Summary statistics  and tests  of significance [Chi squared tests  for  categorical 
variables and Student t tests for continuous variables] were calculated using the software 
package SPSS version 9 on an IBM compatible PC. 
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In this study on pre-tertiary hospital care of patients with CKD 5, there were a 
total of 561 patients who were included in this study. During this period, 10843 patients 
were seen as outpatients by the department of nephrology while 518 patients underwent 
hemodialysis and 82 underwent renal transplantation. 
Demographic Data
Age
Age Group
No. %
< 16 8 1.43
16 - 24 77 13.73
25 - 34 112 19.96
35 - 44 113 20.14
> 44 251 44.74
Table – 4 - Age group profile
The mean age at presentation was 41.1 (± 14.5) years and the range was from 5 
years to 79 years.  It can be seen from Table 4 that the majority of patients were aged 35 
years or above with 44.74% in more than 44 years age bracket.  Figure 4 graphically 
illustrates the data below.
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Gender and Marital Status
The population under study was predominantly male forming 76.4% of cases [429 
of 561 cases]. (Figure 5). Most of the men and the women in the study were married.
Figure 5 – Gender and marital status of patients
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Occupation
The  occupation  profile  of  the  patients  shows  that  occupations  among  these 
patients was varies from that of a manual labourer to a housewife. There were people 
from all walks of life. The occupation profile is shown in Table 5. A large number - 126 
patients  (22.5%) of  the patients  have been designated under  others – which included 
clerks, salesmen, mechanics, telephone operators, welders, barbers, tailors, weavers, bus 
conductors, lawyers and accountants.
Occupation No. %
Housewife 95 16.9
Labourer 76 13.5
Student 69 12.3
Professional 66 11.8
Skilled Worker 65 11.5
Unemployed 64 11.4
Others 126 22.5
Table 5 – Occupation profile
Educational status
Five hundred and one patients (89.3%) had received secondary level education or 
higher. (Table 6). 
Level of Education Number %
College 189 33.7
Higher Secondary 83 14.8
Secondary [6th – 10th] 229 40.8
Primary [1st – 5th] 45 8.0
Illiterate 15 2.7
Table 6 – Educational status
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Socio-economic status
For the purpose of the study, the patients were categorized based on their annual 
total family income. 
They were arbitrarily divided into three groups:
LOW income group – Annual family income         < Rs. 22500
MIDDLE Rs. 22500 – 70000
HIGH         > Rs. 70000
From Table 7, we see that the nearly half the patients (264, 47.1%) were in the middle 
income category with roughly a quarter each in the remaining two groups.
Annual Family Income Number %
Low [< Rs. 22500] 152 27.1
Middle [Rs. 22500 – 70000] 264 47.1
High [> Rs. 70000] 145 25.8
Table 7 – Socio-economic status
Places of origin
The largest number of patients (207, 36.9%) was from the state of West Bengal. 
Sixty-one patients (10.9%) were from the neighbouring country of Bangladesh and 57 
(10.2%) were from our own state of Tamil Nadu. There were patients from all over the 
country and also from the other neighbouring countries of Bhutan and Nepal. Figure 4 
below shows the data graphically. Overall, it was seen that 76.1% were from the eastern 
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and north-eastern regions,  16.9% from southern India and 6% from the northern and 
western regions.
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Figure 6 - Places of origin
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The mean known duration of renal illness was 12.4 ± 23.1 months (range 0 to 184 
months) and the mean known duration of CKD 5 was 3.2 ± 3.5 months (range 0 to 24 
months).
Initial presentation of renal illness
Three hundred and five patients (54.4%) were diagnosed to have CKD 5 on their 
first visit to a doctor. Of these, 22 (7.2%) were diagnosed at Christian Medical College, 
Vellore. Of the 283 (92.8%) who had CKD 5 as their initial presentation of renal illness, 
194 (68.6%) had been to a nephrologists prior to visiting Vellore. (Figure 7)
Native Kidney Disease diagnosed previously
 As can be seen from Table 8, the native kidney disease was unknown in 59.2% of 
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Figure 7 – Initial presentation of CKD
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patients.  Diabetic  nephropathy was  the  most  common diagnosis  that  was  made  (123 
patients, 21.2%) and glomerular disease was previously diagnosed in 47 patients (8.4%) 
(Figure 8).
Native Kidney Disease Number %
Unknown 332 59.2
Diabetic Nephropathy 123 21.8
Glomerular disease 47 8.4
Obstructive Uropathy 18 3.2
Hypertensive nephropathy 15 2.7
CIN 15 2.7
ADPKD 9 1.6
Others 2 0.4
Table 8 - Native Kidney Disease diagnosed previously
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Figure 8 – Native Kidney Disease diagnosed previously
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Previous treating personnel 
About  two-thirds  of  the  patients  (369,  65.8%)  had  been  under  the  care  of  a 
nephrologist  prior  to  visiting  our  centre  and  26.7%  were  seen  earlier  by  a  general 
medicine physician. (Table 9). This is graphically illustrated in figure 9 given below.
Treating Person Number %
Nephrologist 369 65.8
General medicine physician 150 26.7
No Treatment 76 23
Primary doctor 10 1.8
Others 69 9
Table 9 – Previously treating personnel
Referral pattern 
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Figure 9 – Previous treating personnel
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The  majority  were  self-referred  (373,  66  .5%)  while  about  12  per  cent  were 
referred by the treating nephrologist (70, 12.5%) and the physician (64, 11.4%). (Table 
10 and figure 10).  The rest were by other patients (14, 2.5%), their primary physician 
(10, 1.8%) or others.
Referring person Number %
Self-referred 373 66.5
Nephrologist 70 12.5
MD physician 64 11.4
Another patient 14 2.5
Primary doctor 17 3.0
Others 23 4.1
Table 10 – Referral pattern
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Documented investigations done previously 
Upon checking the investigations that had been done previously, (Table 11) it was 
found that a basic hemogram and biochemistry had been done in most of the patients 
(529,  94.3%).  An ultrasound  of  the  abdomen  was  done  in  the  majority  (482,  86%). 
However less than half had quantification of their proteinuria. Testing for the common 
blood borne pathogenic viruses (Hepatitis B virus surface antigen, Anti-Hepatits C virus 
66.5%
Nephrologist
12.5% General Practitioner 
3%
MD physician
11.4%
Another patient
2.5%
Others
4.1%
Self-referred
Figure 10 – Referral pattern
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antibody  and  Human  Immunodeficiency Virus)  was  done  in  only  199  (35.5%),  124 
(22.1%) and 155 patients (27.6%) respectively.  Vaccination against Hepatitis B virus 
was done in less than a quarter of the patients (133, 23.7%).
Investigations done Number %
Hb/PCV, Urine RE, Urea, Creat, K 529 94.3
Ultrasound Abdomen 482 86.0
24 hour protein 269 48.0
HBsAg 199 35.5
Anti HCV 124 22.1
HIV 155 27.6
Table 11 – Documented investigations done previously
Patients with hypertension
 From the study it was seen that 531 patients (94.6%) had hypertension. Of these, 
453 (85.3%) had been prescribed anti-hypertensive medication. Despite this, only 172 
(38%) had a blood pressure less than 130/90 mm of Hg. Overall 329 patients (62%) had 
uncontrolled hypertension at presentation. This is illustrated in figure 11 given below.
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Prior treatment given
As given  in  table  12  below,  dietary recommendations  had been  given  to  344 
patients  (67.3%).  Three  hundred  and  fifty-seven  patients  (63.6%)  were  prescribed 
phosphate binders and 242 (43.6%) were on calcitriol therapy.
Only 87 patients (15.5%) had undergone prior arterio-venous fistula construction. 
One hundred and one patients (18%) were on rhEPO therapy and 228 patients (40.6%) 
had received blood transfusion/s. 
Treatment given Number %
Dietary advice 344 61.3
Phosphate Binders 357 63.6
Vitamin D Therapy 242 43.1
Oral iron 314 56.0
Blood Transfusion 228 40.6
Erythropoietin 101 18.0
AV fistula constructed 87 15.5
Uncontrolle
d
Blood 
Pressure
Untreate
d
78 (14.7 
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 Blood 
Pressure
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mmHg]
No.  with HTN 
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Figure 11 – Patients with Hypertension
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Table 12 – Prior treatment given
Prior patient education
Upon interviewing the patient and his relatives, it was found that 228 patients 
(40.6%) had  adequate  knowledge regarding  CKD 5.  About  a  fifth  were  informed 
regarding  the  need  for  constructing  an  arterio-venous  fistula  for  a  permanent 
hemodialysis  vascular  access  (128,  22.8%)  and  Erythropoeitin  use  (19.1%). 
Knowledge regarding RRT was poor with 248 patients (43.9%) being aware about 
hemodialysis.  Prior  information  regarding  possibility  of  renal  transplantation  was 
known only to 20.9%. Education regarding peritoneal dialysis was done in only 6.8%. 
(Table 13)
Educated regarding Number %
Original Disease 228 40.6
AV fistula 128 22.8
Erythropoeitin 107 19.1
Hemodialysis 248 43.9
Transplantation 117 20.9
Peritoneal Dialysis 38 6.8
Table 13 – Prior patient education
Preference of renal replacement therapy modality
Three  hundred  and  twenty  six  patients  (59%)  said  that  they  would  prefer 
definitive therapy in the form of RRT. Of the modalities, renal transplantation was clearly 
the most preferred (181, 32.3%). One hundred and thirty-two patients (23.5%) expressed 
their preference for maintenance hemodialysis while a small number (13, 2.3%) preferred 
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Continuous  Ambulatory  Peritoneal  Dialysis  (CAPD).  The  rest  either  opted  for 
conservative therapy (182, 32.4%) or were undecided (53, 9.4%). (Table 14 and figure 12)
Decision Number %
Conservative Treatment 182 32.4
Transplantation 181 32.3
Maintenance Hemodialysis 132 23.5
CAPD 13 2.3
Undecided 53 9.4
Table 14 – Decision regarding renal replacement therapy
Care under a nephrologist
Upon evaluating the care given by various treating personnel, it was found that 
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the  care  under  a  nephrologist  was  more  likely to  result  in  appropriate  investigations 
(99.2% vs 90.1%), treatment (97.8% vs 81.3%) and patient education (73.4% vs 39.1%). 
(p<0.001). They were also more likely to opt for renal replacement therapy (p<0.001). 
Blood pressure control did not differ whether treated by a nephrologist or other physician. 
Variable Nephrologist[n = 369] n (%)
Others
[n = 192] n (%) P
Investigations done
Hb/PCV + Urine RE 
Urea + Creat + K (n=561) 361 (97.8) 168 (87.5) < 0.001
HBsAg (n=561) 179 (49) 20 (10) < 0.001
Renal Ultrasound (n=561) 349 (95) 133 (69) < 0.001
BP control 130 (40.4) 46 (35.1) 0.298
Treatment given
Phosphate Binders (n=561) 279 (76) 78 (41) < 0.001
Vitamin D (n=561) 206 (56) 36 (19) < 0.001
HBV vaccination (n=561) 118 (32) 15 (7.8) < 0.001
Dietary advice (n=561) 262 (71) 82 (43) < 0.001
Anti-hypertensive therapy (n=453) 322 (71) 131 (29) < 0.001
BP control (n=453) 130 (40.4) 46 (35.1) 0.298
Blood group testing (n=561) 244 (66) 66 (34.6) < 0.001
AV fistula formation 237 (64) 77 (40) < 0.001
Oral Iron 237 (64) 77 (40) < 0.001
rhEPO 86 (24) 15 (7.9) < 0.001
Prior Patient Education
Original disease 149 (40.6) 54 (28) 0.004
Erythropoietin 95 (25.8) 12 (6.2) < 0.001
AV fistula 114 (31) 14 (7) < 0.001
Hemodialysis 212 (57.4) 34 (17.7) < 0.001
CAPD 32 (8.7) 6 (3.1) 0.013
Renal Transplantation 100 (27) 17 (9) < 0.001
Treatment preferred
Decision regarding RRT 251 (73) 75 (46) < 0.001
Table 15 – Care under a Nephrologist versus other treating personnel
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Variable Nephrologist[n = 369] n (%)
Others
[n = 192] n (%) P
Investigations 366 (99.2) 173 (90.1) < 0.001
Treatment 361 (97.8) 156 (81.3) < 0.001
Prior Patient Education 271 (73.4) 75 (39.1) < 0.001
BP control 130 (40.4) 46 (35.1) 0.298
RRT preferred 251 (73) 75 (46) < 0.001
Table 16 – Care under a Nephrologist versus other treating personnel 
[Overall]
However, upon evaluating for all the necessary facets of care, it was seen that 
although care under a nephrologist was better, all the appropriate investigations had been 
done  in  only  95  patients  (25.7%)  and  only  17  patients  (4.6%)  had  been  educated 
adequately [Table 17].
Variable Nephrologist[n = 369] n (%)
Others
[n = 192] n (%) p
Investigations 95 (25.7) 9 (4.7) < 0.001
Treatment 361 (97.8) 1(0.5) < 0.001
Prior Patient Education 17 (4.6) 1 (0.5) < 0.001
Table 17 – Care under a Nephrologist versus other treating personnel 
[Comprehensive]
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The increasing incidence and prevalence of Chronic Kidney Disease (CKD) has 
made it an important worldwide public health problem. From this perspective, prevention 
of CKD and its progression is undoubtedly an important goal worldwide. 
Optimal treatment of CKD patients includes prevention of metabolic disorders, 
prevention of malnutrition, preservation of quality of life and adequate preparation for 
renal  replacement  therapy  (RRT).  This  translates  into  tight  blood  pressure  control, 
calcium and iron supplements, phosphate binders, vitamin D supplementation, timely use 
of erythropoietin,  dietary counseling,  vaccination against  hepatitis  B virus and timely 
creation of an arterio-venous fistula.58 We looked at these factors in our study.
From the study, it is seen that a basic hemogram, biochemistry and ultrasound had 
been done in most of the patients. However, less than half had quantification of their 
proteinuria.  In  the  perspective  of  factors  affecting  progression  of  CKD,  severity  of 
proteinuria is an important prognosticating factor. Another important investigation that 
was sadly deficient was testing for the common blood borne pathogenic viruses.  The 
importance of this investigation cannot be emphasized. Both hepatitis B virus (HBV) and 
hepatitis C virus (HCV) have important pathogenic role in the etiology of renal illness. 
Further, these have an important bearing upon the patient during his renal replacement 
therapy (both dialysis and transplantation). 
In the area of patient education and treatment, the nephrologist scores over the 
primary or family physician. In this study, it is seen that care under a nephrologist was 
more likely to result in appropriate investigations (99.2% vs 90.1%), treatment (97.8% vs 
81.3%) and patient education (73.4% vs 39.1%). (p<0.001). 
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However, all the necessary investigations had been done in only 25.7% and only 
4.6% had been educated adequately even under a nephrologist.
Worldwide, 30 – 40% of patients are referred to a nephrologist’s care at a very 
late stage of renal disease.54 
Late-referred  patients  were  significantly  less  likely  to  have  received  standard 
therapies  like  rhEPO  (and  consequently  a  lower  hematocrit)  and  vitamin  D 
supplementation,55 vaccination against Hepatitis B54  and a permanent dialysis access in 
place at start of RRT.60 
This results in a poor clinical state at the initiation of RRT59, worse prognosis and 
early death.56  A perceived lack of training and guidelines for referral of patients  with 
CKD and poor communication influences timely referral.61 
This  calls  for  improved  co-operation  between  the  treating  physicians  and  a 
consensus decision on timely referral. The introduction of a new concept of a “medical 
social worker62 is perhaps a right step in this direction. 
Despite 65.8% of the patients being had been under the care of a nephrologist and 
26.7% being under the care of a general medicine physician,  329 patients (62%) had 
uncontrolled  hypertension  at  presentation.  Longer  pre-dialysis  nephrological  care  is 
associated with improved long-term survival and better blood pressure control.63 In this 
study,  however,  there  was  no  difference  in  the  difference  in  blood  pressure  control 
showing a lacuna in management. 
Paucity of symptoms in the initial stages of CKD results in patients not being 
investigated  for  renal  function64  and  54.4%  presented  with  CKD  5  as  the  initial 
presentation of renal disease. This underscores the value of periodic medical evaluation 
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for  the  otherwise  healthy  individuals  of  our  community  especially  those  at  risk  for 
developing CKD.  For the self same reason of late presentation, the native kidney disease 
was  unknown  in  59.2%  of  cases.  Diabetic  nephropathy  was  the  commonest  known 
etiology (21.8%).
Finally vaccination against HBV is an important measure to attempt prevention in 
a patient with CKD. In this study, less than a quarter of the patients had been vaccinated 
against  HBV infection.  Vaccination of all  patients  with CKD needs to be carried out 
meticulously and with double dose of the vaccine. The low vaccination rate is a concern 
in the dialysis population leading to inadequate protection in this population.24
This study highlights the need for a country-wide effort to curtail progression to 
CKD  5.  This  effort  begins  with  educating  the  medical  practitioners  throughout  the 
country  about  the  disease,  its  prevention,  and  steps  to  slow  progression;  also  about 
optimal medical management including timely referral to a nephrologist. 
In this study on “evaluation of pre-tertiary hospital care of patients with Chronic Kidney 
Disease Stage 5”, the following observations were made:
1. The mean known duration of renal illness was 12.4 ± 23.1 months (range 0 to 184 
months).
2. The  mean  known  duration  of  CKD 5  was  3.2  ±  3.5  months  (range  0  to  24 
months).
3. CKD 5 was the initial presentation of renal illness in 54.4% of cases.
4. 65.8% had been under care of a nephrologist while 26.7% had been under care of 
a general medicine physician.
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5. Two-thirds  of  the patients  had  been  self-referred for  a  second opinion on the 
diagnosis of their illness.
6. Although a basic hemogram and biochemistry had been done in most (94.3%) and 
an ultrasonogram in 86%, testing for the blood borne viruses (HIV, HCV and 
HBsAg) was done in only 27 to 35% of patients. Vaccination against hepatitis B 
was poor (23.7%).
7. Adequate blood pressure control was achieved in only 38% of the patients.
8. Care under a nephrologist was more likely to result in appropriate investigations 
(99.2% vs 90.1%), treatment (97.8% vs 81.3%) and patient education (73.4% vs 
39.1%).  (p<0.001).  They  were  also  more  likely  to  opt  for  renal  replacement 
therapy (p<0.001). 
9. Blood pressure control did not differ whether treated by a nephrologist or other 
physician. 
10. Upon evaluating for comprehensive care, although care under a nephrologist was 
better,  all the  appropriate  investigations  had  been  done  in  only  95  patients 
(25.7%) and only 17 patients (4.6%) had been educated adequately.
National  Kidney Foundation.  K/DOQI clinical  practice  guidelines  for  chronic  kidney 
disease:  evaluation,  classification,  and stratification.  Am J Kidney Dis.  2002;39:Suppl 
1:S1-S266.
61
1. Shemesh O, Golbetz H, Kriss JP,  et al.  Limitations of creatinine as a filtration 
marker in glomerulopathic patients. Kidney Int. 1985;28:830–838.
2. Cockcroft  DW,  Gault  MH.  Prediction  of  creatinine  clearance  from  serum 
creatinine. Nephron. 1976;16:31–41.
3. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and 
blood-pressure control on the progression of chronic renal disease. N Engl J Med. 
1994;330:877–884. 
4. Levey  AS,  Bosch  JP,  Lewis  JB,  et  al.  A  more  accurate  method  to  estimate 
glomerular filtration rate from serum creatinine: a new prediction equation.  Ann 
Intern Med. 1999;130:461-70.
5. Coresh J,  Wei GL,  McQuillan G,  et al. Prevalence of high blood pressure and 
elevated  serum  creatinine  level  in  the  United  States:  findings  from the  third 
National  Health  and  Nutrition  Examination  Survey (1988–1994).  Arch  Intern 
Med. 2001;161:1207-16
6. Collins AJ. Excerpts from the United States Renal Data System 2004 annual data 
report: atlas of end-stage renal disease in the United States.  Am J Kidney Dis.  
2005;45(1 Suppl 1): A5-7
7. Ellis PA, Cairns HS. Renal impairment in elderly patients with hypertension and 
diabetes. QJM. 2001:94:261-5.
8. Mani MK. Prevention of chronic kidney failure at the community level.  Kidney 
Int. 2003;63:Suppl 83:S86-9.
9. Agarwal  SK.  Chronic  kidney disease  and  its  prevention  in  India.  Kidney  Int. 
2005;98:S41-5. 
62
10. Hostetter  TH. Prevention of end-stage renal disease due to type 2 diabetes.  N 
Engl J Med. 2001;345:910–12.
11. Hellstrom L, Elinder CG, Dahlberg B,  et al.  Cadmium exposure and end-stage 
renal disease. Am J Kidney Dis. 2001;38:1001-8.
12. Gofin R. The health status of elderly men: a community study.  Public Health. 
1982;96:345-54.
13. Jacobsen SJ, Oesterling JE, Lieber MM. Community-based population studies on 
the natural history of prostatism. Curr Opin Urol. 1995;5:13–17. 
14. Kristal B, Shasha SM, Labin L,  et al, Estimation of quantitative proteinuria by 
using  the  protein–creatinine  ratio  in  random  urine  samples.  Am  J  Nephrol  
1988;8:198–203. 
15. Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu 
Rev Med 39:465–490.
16. Brazy PC, Stead WW, Fitzwilliam J F. Progression of renal insufficiency: role of 
blood pressure. Kidney Int. 1989;35:670-4. 
17. Rambausek M, Rhein C, Waldherr, R,  et al,  Hypertension in chronic idiopathic 
glomerulonephritis:  analysis  of  311  biopsied  patients.  Eur  J  Clin  Invest.  
1989;19,176–180.
18. Parving HH, Andersen AR, Smidt UM,  et al. Early aggressive antihypertensive 
treatment  reduces  rate  of  decline  in  kidney  function  in  diabeticnephropathy. 
Lancet. 1983:1:1175-9.
19. Parving HH, Andersen AR, Smidt UM, et al. Effect of antihypertensive treatment 
on kidney function in diabetic nephropathy. Br Med J. 1987;294:1443–7.
63
20. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and 
blood-pressure control on the progression of chronic renal disease. N Engl J Med. 
1994;330:877–84.
21. Chobanian AV, Bakris GL, Black HR,  et al.   The Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
22. Bergstrom J, Alvestrand A, Bucht H, et al. Progression of chronic renal failure in 
man is retarded with more clinical follow-ups and better blood pressure control. 
Clin Nephrol. 1986;25:1–6.
23. George J, John GT, Jacob CK,  et al.  Active immunization against  hepatitis  B 
infection  in  hemodialysis  population  –  some  problems.  Natl  Med  J  India. 
1994;7:115-6.
24. Fouque,  D.  Controlled  low protein  diets  in  chronic  renal  insufficiency:  meta-
analysis. Br Med J. 1992;304:216–20.
25. Kasiske BL, Lakatua JD, Ma JZ, et al.  A meta-analysis of the effects of dietary 
protein  restriction  on  the  rate  of  decline  in  renal  function.  Am J  Kidney  Dis. 
1998;31:954-61.
26. Rix M, Andreassen H, Eskilden P,  et al.  Bone mineral density and biochemical 
markers of bone turnover in patients with predialysis chronic renal failure. Kidney 
Int. 1999;56:1084-93.
27. Roe S, Cassidy MJD. Diagnosis and monitoring of renal osteodystrophy.  Curr 
Opin Nephrol Hypertens. 2000;9:675–681.
28. Baker LR, Abrams L, Roe CJ,  et al.  1,25(OH)2D3 administration in moderate 
64
renal failure: a prospective double-blind trial. Kidney Int. 1989;35:661–669.
29. Cunningham  J.  What  is  the  optimal  regimen  for  vitamin  D?  Kidney  Int. 
1999;56:S59–64. 
30. Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic 
renal insufficiency. Am J Kidney Dis. 2001;38:803–812.
31. Akmal M, Sawelson S,  Karubian F,  et  al. The prevalence and significance of 
occult  blood  loss  in  patients  with  predialysis  advanced  chronic  renal  failure 
(CRF), or receiving dialytic therapy. Clin Nephrol. 1994;42:198–202.
32. Kuriyama S, Tomonari H, Yoshida H, et al. Reversal of anemia by erythropoietin 
therapy retards the progression of chronic renal failure, especially in nondiabetic 
patients. Nephron 1997;77:176–85.
33. Jungers P, Choukroun G, Oualim Z,  et al.  Beneficial influence of recombinant 
human erythropoietin therapy on the rate of progression of chronic renal failure in 
predialysis patients. Nephrol Dial Transplant 2001;16 , 307–312.
34. Attman PO, Samuelsson, O, Alaupovic P. Lipid metabolism and renal failure. Am 
J Kidney Dis. 1993;21:373–592.
35. Fried  LF,  Forrest  KY,  Ellis  D, et  al.  Lipid  modulation  in  insulin-dependent 
diabetes mellitus:  effect  on microvascular outcomes.  J  Diabetes Complications 
2001;15:113–19.
36. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of 
renal disease: a meta-analysis. Kidney Int. 2001;59:260–9. 
37. Biesenbach G, Grafinger P, Janko O, et al. Influence of cigarette-smoking on the 
progression  of  clinical  diabetic  nephropathy  in  type  2  diabetic  patients.  Clin 
65
Nephrol. 1997;48, 146–150.
38. Orth SR; Stöckmann A; Conradt C, et al.  Smoking as a risk factor for end-stage 
renal failure in men with primary renal disease. Kidney Int.1998;54:926–31.
39. Astor  BC,  Eustace  JA,  Powe  NR,  et  al.  Timing  of  nephrologist  referral  and 
arteriovenous access use:  the CHOICE study.  Am J Kidney Dis.  2001;38:494–
501.
40. Shenmesh O, Golbetz H, Kriss JP,  et al. Limitations of creatinine as a filtration 
marker in glomerulopathic patients. Kidney Int. 1985;28:830–38.
41. Perrone  RD,  Madias  NE,  Levey  AS.  Serum  creatinine  as  an  index  of  renal 
function: new insights into old concepts. Clin. Chem. 1992;38, 1933–1953. 
42. Nilsson-Ehle P,  Grub A. New markers  for the determination of GFR: iohexol 
clearance and cystatin  C serum concentration.  Kidney Int. 1994;46(Suppl.  47), 
S17–S19. 
43. Mitch  WE,  Walser  M,  Buffington  GA,  et  al. A simple  method of  estimating 
progression of chronic renal failure. Lancet 1976;2:1326–8.
44. Leumann EP. Progression of renal insufficiency in pediatric patients: estimation 
from serum creatinine. Helv Paediatr Acta 1978;33:25–35.
45. Rutherford WE, Blondin J, Miller J P,  et al.  Chronic progressive renal disease: 
rate of change of serum creatinine concentration. Kidney Int. 1977;11:62–70. 
46. Winston JA, Burns GC, Klotman PE. The human immunodeficiency virus (HIV) 
epidemic and HIV-associated nephropathy. Semin Nephrol. 1998;18:373–377.
47. Mansfield  PF,  Hohn  DC,  Fornage  BD,  et  al. Complications  and  failures  of 
subclavian-vein cathererization. N Engl J Med. 1994;331:1735–38.
66
48. Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term 
dialysis  on the subsequent  survival  of  renal  transplants from living donors.  N 
Engl J Med. 2001;344:726–31.
49. Malangone JM, Abuelo JG, Pezzullo JC,  et al. Clinical and laboratory features of 
patients  with  chronic  renal  disease  at  the  start  of  dialysis.  Clin  Nephrol.  
1989;31:77–87.
50. Ratcliffe PJ, Phillips RE, Oliver DO. Late referral for maintenance dialysis.  Br 
Med J. 1984;288:441–3.
51. Khan IH, Catto GR, Edward N,  et al.  Chronic renal failure: factors influencing 
nephrological referral. QJM. 1994;87:559–64.
52. Sesso R, Belasco AG. Late diagnosis of chronic renal failure and mortality on 
maintenance dialysis. Nephrol Dial Transplant. 1996;11:2417–20.
53. Ellis PA, Reddy V, Bari N,  et al.  Late referral of end-stage renal failure. QJM. 
1998;91:727–32.
54. Roderick P, Jones C, Tomson C,   et al.  Late referral for dialysis: improving the 
management of chronic renal disease. QJM. 2002;95:363–370.
55. Innes A, Rowe PA, Burden RP,  et al. Early deaths on renal replacement therapy: 
the  need  for  early  nephrological  referral.  Nephrol  Dial  Transplant. 
1992:7:467-471
56. Treatment  of  Adult  Patients  with  Renal  Failure,  2nd  edn.  London,  Renal 
Association and Royal College of Physicians,1997.
57. Pereira  BJ.  Optimization  of  pre-ESRD  care:  the  key  to  improving  dialysis 
outcomes. Kidney Int. 2000;57:351-65. 
67
58. Arora P, Obrador GT, Ruthazer R, et al. Prevalence, predictors, and consequences 
of  late  nephrology referral  at  a  tertiary care  center.  J  Am Soc Nephrol.  1999 
Jun;10(6):1281-6. 
59. Roderick P, Jones C, Drey N, et al. Late referral for ESRD: a region-wide survey 
in South West England. Nephrol Dial Transplant. 2002;17:1252–59.
60. Grace  JF,  Armstrong  D.  Referral  to  hospital:  perceptions  of  patients,  general 
practitioners  and  consultants  about  necessity  and  suitability  of  referral.  Fam 
Pract. 1987:4:170-5.
61. Best Clinical Practice Guidelines for Chronic Kidney Disease in India,  Indian J 
Nephrol. 2005;15:Suppl 1:S1-S6.
62. Jungers  P,  Massy ZA,  Nguyen-Khoa  T,  et  al.  Longer  duration  of  predialysis 
nephrological  care  is  associated  with  improved  long-term survival  of  dialysis 
patients. Nephrol Dial Transplant. 2001;16:2357-64.
63. Jungers P,  Zingraff  J,  Albouze G,  et al.  Late referral  to maintenance dialysis: 
detrimental consequences. Nephrol Dial Transplant. 1993;8:1089-93.
68
Evaluation of Pre-Tertiary Hospital Care of Patients with CKD Stage 5
Serial No:
Name: Age: Sex: M/F
Marital Status: Single / Married / Widow (or) Divorce 
Education: 1. Illiterate 2. Primary (1-5)  3. Secondary (6-10) 4. HSC  5. College
Occupation:  1. Labourer  2. Skilled worker  3. Professional  4. House wife  5. Student
          
          6. Other  7. Unemployed
State of Residence [Code No.]:  
Socio Economic Status [income]:     Low      Middle      High
     [≤22500]   [22501 – 70000]   [≥70001]
Treated By: 0. None  1. MD Physician  2. Nephrologist   3. Primary doctor
                    4. Another   5.  Others.
Referral     : 0. None  1. MD Physician  2. Nephrologist   3. Primary doctor
                    4. Another patient   5.  Others.
Renal Disease:  RD and CKD-5
Duration of proven Renal Disease (months) :     
Diabetic            : Yes / No
Native Kidney Disease                      :
HB / PCV + Urine RE done            : Yes / No
Urea + Creat + K done                         : Yes / No
Proteinuria (> 500mg)                         : Yes / No
Biopsy Done (if indicated)            : Yes / No / Not applicable
Biopsy diagnosis:
HBV tested:            :              Yes / No
 At  RD  diagnosis  /  At  CKD-5 
diagnosis
HCV tested            :              Yes / No
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                                                                               At RD diagnosis / At CKD-5 diagnosis
HIV tested            :              Yes / No
                                                                               At RD diagnosis / At CKD-5 diagnosis
Ultrasound            :              Yes / No
                                                                               At RD diagnosis / At CKD-5 diagnosis
Anti-Hypertensives
(to target 130/90 mm Hg)            : Yes / No
                                                                               At RD diagnosis / At CKD-5 diagnosis
Is the BP control adequate            :              Yes / No
Phosphate binders            : Yes / No
                                                                               At RD diagnosis / At CKD-5 diagnosis
HBV vaccination            : Yes / No
                                                                               At RD diagnosis / At CKD-5 diagnosis
Dietary advice            : Yes / No
                                                                               At RD diagnosis / At CKD-5 diagnosis
Immunosuppression            :    Yes / No
                                                                               At RD diagnosis / At CKD-5 diagnosis
Therapy of CKD-5
Duration of CKD-5 (months):
1. AVF formation: Yes / No          2. Iron  (Oral):  Yes / No    3. NA Iron (IV) : Yes / No /NA
4. EPO : Yes / No / NA          5. Vitamin D :   Yes / No / NA 
6. Blood Transfusion: Yes / No / NA  7. Blood Grouping :  Yes / No / NA
Practical understanding (including costs):
1.Original disease  : Yes / No 2.Hemodialysis : Yes / No 3.CAPD: Yes / No
4. Transplant          :  Yes / No   5. EPO : Yes / No                        6. AVF : Yes / No
Final Decision:
1. Undecided 2. HD  3. CAPD     4. HD & TX     5.  Medical treatment only
State of residence (option codes):
1. Andaman &     Nicobar 2. Andra Pradesh 3. Arunachal pradesh 4. Assam
5. Bihar 6. Chandigarh 7. Chattisgarh 8. Dadar & Nagar
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9. Daman & Diu 10. Delhi 11. Goa 12. Gujarat
13. Hariyana 14. Hemacal 15. J & K 16. Jharkand
17. Karnataka 18. Kerala 19. Lakshwadweep 20. MP
21. Maharastra 22. Manipur 23. Meghalaya 24. Mizroam
25. Nagaland 26. Orissa 27. Pondichery 28. Punjab
29. Rajastan 30. Sikkim 31. TN 32. Tripura
33. Uttar Pradesh 34. Uttranchal 35. WB 36. Bangladesh
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